This report examines how biosimilar competition has reshaped European pharmaceutical markets, driving price reductions, expanding patient access, and generating healthcare savings. It analyzes uptake trends across therapy areas and countries, highlighting policy environments that accelerate adoption. The findings show that sustained competition fosters reinvestment into innovation while improving affordability. The paper also identifies barriers to optimal biosimilar penetration and recommends policy and contracting strategies to maintain long-term market sustainability, ensure supply security, and maximize value for healthcare systems and patients.

Join for free to read